<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453427</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-103662</org_study_id>
    <nct_id>NCT00453427</nct_id>
  </id_info>
  <brief_title>Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas</brief_title>
  <acronym>ACCAPELA</acronym>
  <official_title>Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to:&#xD;
&#xD;
        1. establish the safety and dose limiting toxicities of combining alemtuzumab with CHOP&#xD;
           chemotherapy for patients with newly diagnosed aggressive T-cell lymphomas; and&#xD;
&#xD;
        2. to measure the pharmacokinetics of alemtuzumab used in different subcutaneous doses and&#xD;
           schedules.&#xD;
&#xD;
      This will then determine the dose with the highest achievable drug levels with acceptable&#xD;
      toxicities worthy of further investigation.&#xD;
&#xD;
      The secondary objectives are to:&#xD;
&#xD;
        1. establish the efficacy of combination alemtuzumab with CHOP chemotherapy; and&#xD;
&#xD;
        2. to measure the effects of combination alemtuzumab with CHOP chemotherapy on T-cell&#xD;
           reconstitution and cytomegalovirus (CMV) reactivation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aggressive peripheral T-cell lymphomas account for 10 - 15% of all Non-Hodgkin's Lymphoma&#xD;
      (NHL) and present with more adverse prognostic features than aggressive histology B-cell NHL&#xD;
      . Correspondingly, they have an overall poorer prognosis than B-cell lymphomas, achieving&#xD;
      lower complete response rates, freedom from progression and overall survival with&#xD;
      conventional anthracycline-based CHOP (cyclophosphamide, doxorubicin, vincristine and&#xD;
      prednisone) chemotherapy. Fewer than 30% of patients are cured with therapy. New treatments&#xD;
      that replicate the improved survivals with chemo-immunotherapy for B-cell lymphomas are&#xD;
      needed. Alemtuzumab is a humanized murine antibody that binds to a ubiquitous lymphoid marker&#xD;
      CD52 and is efficacious (as monotherapy) in related lymphoproliferative diseases. Combining&#xD;
      alemtuzumab with CHOP chemotherapy may improve the response rates and outcomes of patients&#xD;
      with this sub-type of NHL. The combination must be first tested in a dose escalation fashion&#xD;
      to establish the dosage of the doublet because of the potential for overlapping or&#xD;
      exaggerated toxicities.&#xD;
&#xD;
      This prospective, multi-center, open label Phase I-II study will enroll 22-84 patients with&#xD;
      newly diagnosed previously untreated aggressive histology peripheral T-cell lymphomas. In the&#xD;
      Phase I component, patients will be sequentially enrolled in cohorts of three patients and&#xD;
      treated with increasing doses of alemtuzumab administered in combination with standard CHOP&#xD;
      chemotherapy. When the maximal tolerated dose is determined, this dose and schedule will then&#xD;
      be tested in up to 46 patients using a Simon two stage Phase II design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity</measure>
    <time_frame>8 cycles of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>Post cycle 3 and Post cycle 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumour response</measure>
    <time_frame>Post Cycle 3 and Post Cycle 8 Q 6 months in Followup</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic analysis</measure>
    <time_frame>Day 1 of 8 Cycles of treatment and Post Last Dose on Day 3,6,10,13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological monitoring</measure>
    <time_frame>Baseline Day 1 On Treatment Day 1 Cycle 4 and Cycle 8 and 6 months Follow-up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Peripheral T-cell Lymphomas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab (Campath-1H)</intervention_name>
    <description>The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (&gt; 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years of age or older at time of enrollment,&#xD;
&#xD;
          -  Histologically proven and centrally reviewed CD52+ T-cell NHL Stages 2-4 including the&#xD;
             following nodal and extranodal subtypes:&#xD;
&#xD;
        Nodal:&#xD;
&#xD;
          -  Peripheral T-cell lymphoma not otherwise specified (PTL NOS)&#xD;
&#xD;
          -  Angioimmunoblastic lymphadenopathy (AILD)&#xD;
&#xD;
          -  ALK 1 negative anaplastic large cell NHL&#xD;
&#xD;
        Extranodal:&#xD;
&#xD;
          -  Hepatosplenic&#xD;
&#xD;
          -  Enteropathy-associated&#xD;
&#xD;
          -  Panniculitic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with chemotherapy or radiation with the exception of up to 1 cycle&#xD;
             of CHOP chemotherapy.&#xD;
&#xD;
          -  Expected survival &lt; 4 months.&#xD;
&#xD;
          -  ECOG performance status &gt; 3.&#xD;
&#xD;
          -  Inadequate haematologic function (Hb &lt; 85g/L, ANC &lt; 1000/mm3, or platelet count &lt;&#xD;
             75,000/mm3) unless directly attributable to the NHL.&#xD;
&#xD;
          -  Inadequate hepatic function (total bilirubin &gt; 35μmol/L, alkaline phosphatase &gt; 2x UL&#xD;
             normal, AST/ALT &gt; 2x UL normal)&#xD;
&#xD;
          -  Inadequate renal function (serum creatinine &gt; 130μmol/L), unless directly attributable&#xD;
             to the NHL.&#xD;
&#xD;
          -  Non-measurable or non-evaluable disease, according to criteria of Cheson et al49.&#xD;
&#xD;
          -  Geographically inaccessible for follow-up&#xD;
&#xD;
          -  Known hypersensitivity to study drugs&#xD;
&#xD;
          -  Serious illnesses that may interfere with subject compliance, determination of&#xD;
             causality of adverse events or would compromise other protocol objectives.&#xD;
&#xD;
          -  Known HIV positivity or other pre-existing immunodeficiency (e.g., post-organ&#xD;
             transplant).&#xD;
&#xD;
          -  Known CNS involvement with lymphoma (tests to investigate CNS involvement are required&#xD;
             only if clinically indicated).&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women who are of childbearing potential but are not using effective contraception. Men&#xD;
             with reproductive potential who are not using effective contraception.&#xD;
&#xD;
          -  Previous malignancy within the last 5 years with the exception of cervical carcinoma&#xD;
             in situ or non melanoma skin cancer.&#xD;
&#xD;
          -  Nasal natural killer (NK) T-cell NHL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rena Buckstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre, Odette Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTL NOS</keyword>
  <keyword>AILD</keyword>
  <keyword>NHL</keyword>
  <keyword>CHOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

